Radius Health, a biotech developing treatments to restore bone density in osteoporosis patients, announced terms for its IPO on Friday. The Cambridge, MA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, it would command a fully diluted market value of $411 million. Radius Health, which was founded in 2003, plans to list on the NASDAQ under the symbol RDUS. Jefferies and Cowen & Company are the joint bookrunners on the deal.
